What is Ultragenyx Pharmaceutical's total revenue?

Ultragenyx Pharmaceutical (RARE) reported total revenue of $136M in Q1 2026.

How has Ultragenyx Pharmaceutical's total revenue changed year-over-year?

Ultragenyx Pharmaceutical's total revenue decreased by 2.2% year-over-year, from $139M to $136M.

What is the long-term trend for Ultragenyx Pharmaceutical's total revenue?

Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's total revenue has grown at a 17.6% compound annual growth rate (CAGR), from $351.41M to $672.71M.

What does total revenue mean?

The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ultragenyx Pharmaceutical RARE Total Revenue

Total Revenue at other companies

Eli LillyLLY

$19.8B+55.5%

AmgenAMGN

$8.62B+5.8%

Ionis PharmaceuticalsIONS

$246.09M+87.0%

Arrowhead ResearchARWR

$73.74M-86.4%

CRISPR TherapeuticsCRSP

$1.46M+68.6%

ModernaMRNA

$389M+260%

Segments

By geography

See full

North America$59M+1.7%

Latin America$42M-23.6%

EMEA$31M+34.8%

Asia Pacific$4M+33.3%

By product

See full

Collaboration And Royalty$93M-9.7%

Royalty$47M-2.1%

Non Cash Royalty$20M+5.3%

Other financials

Income statement

See full

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

See full

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

See full

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

See full

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

See full

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

See full

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's total revenue?: Ultragenyx Pharmaceutical (RARE) reported total revenue of $136M in Q1 2026.
How has Ultragenyx Pharmaceutical's total revenue changed year-over-year?: Ultragenyx Pharmaceutical's total revenue decreased by 2.2% year-over-year, from $139M to $136M.
What is the long-term trend for Ultragenyx Pharmaceutical's total revenue?: Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's total revenue has grown at a 17.6% compound annual growth rate (CAGR), from $351.41M to $672.71M.
What does total revenue mean?: The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.